Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same

The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Castan, Catherine, Meyrueix, Remi, Soula, Gerard
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Castan, Catherine
Meyrueix, Remi
Soula, Gerard
description The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine. The invention is applicable to the treatment of type II diabetes.
format Patent
fullrecord <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_08197850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>08197850</sourcerecordid><originalsourceid>FETCH-uspatents_grants_081978503</originalsourceid><addsrcrecordid>eNqNizsKAjEQQNNYiHqHucDCiohrvSg2dvYyJrNJID9mssje3ggewOLxmvfWyt3JeO0TwQuFDOQEmKrv3FKIbVg0UvQaGpw1FpkDCbx9dVA4h5xse5gCtbmNBiJVlw1MmVtABdknC4KRtmo1YRDa_bxRcL08xls3S8FKqcrTMn7VD_vzaTj2hz-SD-x4Qbw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same</title><source>USPTO Issued Patents</source><creator>Castan, Catherine ; Meyrueix, Remi ; Soula, Gerard</creator><creatorcontrib>Castan, Catherine ; Meyrueix, Remi ; Soula, Gerard ; Flamel Technologies</creatorcontrib><description>The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine. The invention is applicable to the treatment of type II diabetes.</description><language>eng</language><creationdate>2012</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8197850$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,780,802,885,64039</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8197850$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Castan, Catherine</creatorcontrib><creatorcontrib>Meyrueix, Remi</creatorcontrib><creatorcontrib>Soula, Gerard</creatorcontrib><creatorcontrib>Flamel Technologies</creatorcontrib><title>Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same</title><description>The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine. The invention is applicable to the treatment of type II diabetes.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2012</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNqNizsKAjEQQNNYiHqHucDCiohrvSg2dvYyJrNJID9mssje3ggewOLxmvfWyt3JeO0TwQuFDOQEmKrv3FKIbVg0UvQaGpw1FpkDCbx9dVA4h5xse5gCtbmNBiJVlw1MmVtABdknC4KRtmo1YRDa_bxRcL08xls3S8FKqcrTMn7VD_vzaTj2hz-SD-x4Qbw</recordid><startdate>20120612</startdate><enddate>20120612</enddate><creator>Castan, Catherine</creator><creator>Meyrueix, Remi</creator><creator>Soula, Gerard</creator><scope>EFH</scope></search><sort><creationdate>20120612</creationdate><title>Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same</title><author>Castan, Catherine ; Meyrueix, Remi ; Soula, Gerard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_081978503</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Castan, Catherine</creatorcontrib><creatorcontrib>Meyrueix, Remi</creatorcontrib><creatorcontrib>Soula, Gerard</creatorcontrib><creatorcontrib>Flamel Technologies</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Castan, Catherine</au><au>Meyrueix, Remi</au><au>Soula, Gerard</au><aucorp>Flamel Technologies</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same</title><date>2012-06-12</date><risdate>2012</risdate><abstract>The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine. The invention is applicable to the treatment of type II diabetes.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_grants_08197850
source USPTO Issued Patents
title Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A42%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Castan,%20Catherine&rft.aucorp=Flamel%20Technologies&rft.date=2012-06-12&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E08197850%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true